Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases
S Siebert, A Tsoukas, J Robertson, I McInnes - Pharmacological reviews, 2015 - Elsevier
The human immune system involves highly complex and coordinated processes in which
small proteins named cytokines play a key role. Cytokines have been implicated in the …
small proteins named cytokines play a key role. Cytokines have been implicated in the …
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
X Mariette, M Matucci-Cerinic, K Pavelka… - Annals of the rheumatic …, 2011 - Elsevier
Objectives This project was undertaken to assess the risk of malignancy in patients with
rheumatoid arthritis treated with tumour necrosis factor inhibitors (TNFi) in clinical practice …
rheumatoid arthritis treated with tumour necrosis factor inhibitors (TNFi) in clinical practice …
Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab …
Objective To compare tumor necrosis factor α inhibitors directly regarding the rates of
treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis …
treatment response, remission, and the drug survival rate in patients with rheumatoid arthritis …
Rate of discontinuation and drug survival of biologic therapies in rheumatoid arthritis: a systematic review and meta-analysis of drug registries and health care …
Objectives. To assess the proportion of RA patients who discontinued biologics in world
registries and health care databases and to identify causes and predictors of …
registries and health care databases and to identify causes and predictors of …
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL …
AR Balanescu, G Citera, V Pascual-Ramos… - Annals of the rheumatic …, 2022 - Elsevier
Objectives To characterise infections in patients with rheumatoid arthritis (RA) in ORAL
Surveillance. Methods In this open-label, randomised controlled trial, patients with RA …
Surveillance. Methods In this open-label, randomised controlled trial, patients with RA …
Systematic review with network meta‐analysis: the efficacy of anti‐TNF agents for the treatment of Crohn's disease
Background Anti‐tumour necrosis factor‐alpha agents (anti‐TNF) are effective therapies for
the treatment of Crohn's disease (CD), but their comparative efficacy is unknown. Aim To …
the treatment of Crohn's disease (CD), but their comparative efficacy is unknown. Aim To …
Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
M Neovius, EV Arkema, H Olsson, JK Eriksson… - Annals of the rheumatic …, 2015 - Elsevier
Objective To compare drug survival on adalimumab, etanercept and infliximab in patients
with rheumatoid arthritis (RA). Methods Patients with RA (n= 9139; 76% women; mean age …
with rheumatoid arthritis (RA). Methods Patients with RA (n= 9139; 76% women; mean age …
Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris
R Gniadecki, K Kragballe, TN Dam… - British Journal of …, 2011 - academic.oup.com
Background Adherence to treatment is an indicator of treatment success. Long‐term data on
adherence to biologic treatment in psoriasis are lacking. Objectives To compare the tumour …
adherence to biologic treatment in psoriasis are lacking. Objectives To compare the tumour …
[HTML][HTML] Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated …
M Stevenson, R Archer, J Tosh… - Health technology …, 2016 - pmc.ncbi.nlm.nih.gov
OBJECTIVES Rheumatoid arthritis (RA) is a chronic inflammatory disease associated with
increasing disability, reduced quality of life and substantial costs (as a result of both …
increasing disability, reduced quality of life and substantial costs (as a result of both …
Clinical predictors of response and discontinuation of belimumab in patients with systemic lupus erythematosus in real life setting. Results of a large, multicentric …
Objective To investigate efficacy, safety and survival of belimumab and to identify predictors
of drug response and drug discontinuation in patients with active SLE in clinical practice …
of drug response and drug discontinuation in patients with active SLE in clinical practice …